Heron Therapeutics Inc (NASDAQ:HRTX) Expected to Announce Quarterly Sales of $33.93 Million

Brokerages expect that Heron Therapeutics Inc (NASDAQ:HRTX) will post $33.93 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Heron Therapeutics’ earnings, with estimates ranging from $30.00 million to $38.00 million. Heron Therapeutics reported sales of $19.79 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 71.5%. The company is expected to announce its next earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $129.34 million for the current financial year, with estimates ranging from $124.00 million to $139.30 million. For the next year, analysts forecast that the company will post sales of $175.10 million, with estimates ranging from $122.70 million to $253.70 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The company had revenue of $36.66 million for the quarter, compared to analysts’ expectations of $31.04 million.

Several analysts recently weighed in on HRTX shares. Stifel Nicolaus reissued a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a research note on Monday, August 5th. Evercore ISI reissued a “buy” rating and issued a $75.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, August 13th. Cowen reissued a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, October 1st. Zacks Investment Research raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. Finally, BidaskClub cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 26th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $50.57.

Shares of Heron Therapeutics stock traded up $1.17 during trading on Friday, hitting $20.98. The company’s stock had a trading volume of 71,574 shares, compared to its average volume of 1,322,903. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.01 and a quick ratio of 3.70. Heron Therapeutics has a 52 week low of $15.68 and a 52 week high of $31.81. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -8.60 and a beta of 1.42. The stock has a 50-day moving average price of $18.95 and a two-hundred day moving average price of $18.88.

In other news, insider John Poyhonen purchased 11,105 shares of the business’s stock in a transaction on Monday, September 30th. The shares were acquired at an average price of $22.62 per share, with a total value of $251,195.10. Also, CEO Barry D. Quart purchased 4,571 shares of the business’s stock in a transaction on Thursday, October 3rd. The shares were purchased at an average cost of $17.50 per share, for a total transaction of $79,992.50. Following the transaction, the chief executive officer now directly owns 90,081 shares of the company’s stock, valued at approximately $1,576,417.50. The disclosure for this purchase can be found here. Insiders have acquired 306,533 shares of company stock worth $5,421,185 in the last ninety days. Insiders own 12.56% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers boosted its position in Heron Therapeutics by 1.1% during the third quarter. Rhumbline Advisers now owns 100,802 shares of the biotechnology company’s stock valued at $1,865,000 after acquiring an additional 1,124 shares during the last quarter. Chartwell Investment Partners LLC boosted its position in Heron Therapeutics by 1.1% during the second quarter. Chartwell Investment Partners LLC now owns 100,171 shares of the biotechnology company’s stock valued at $1,862,000 after acquiring an additional 1,129 shares during the last quarter. Meadow Creek Investment Management LLC bought a new stake in Heron Therapeutics during the second quarter valued at $27,000. Congress Park Capital LLC boosted its position in shares of Heron Therapeutics by 1.5% during the 3rd quarter. Congress Park Capital LLC now owns 111,265 shares of the biotechnology company’s stock worth $2,058,000 after purchasing an additional 1,600 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Heron Therapeutics by 75.6% during the 2nd quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,769 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: Float

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.